GOTHENBURG, Sweden, November 12 /PRNewswire/ -- Cellectricon, a leading provider of advanced screening solutions for drug discovery, has today received its most significant and largest single order to date. The order includes three Cellaxess(R)HT systems and the customer is a leading US biotech firm.
"An order of this magnitude proves the system's unique features and value, and validates Cellectricon's strategy to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations." says Jonas Ohlsson, CEO at Cellectricon. "Cellectricon has developed the Cellaxess(R)HT system in close collaboration with leading pharmaceutical companies and academic research groups to meet the rapidly growing demand for a true high throughput transfection screening technology, capable of reagent-free delivery of genetic material to biologically relevant cell types."
Cellaxess(R)HT is the world's first fully automated workstation for high throughput RNAi screening on biologically relevant cell types. The system enables reagent free delivery of siRNA and cDNA to a wide range of primary cells and cell lines with excellent efficiency and viability at a throughput of 50, 000 wells per day. Cellaxess(R)HT is first of its kind on the market and will significantly impact target discovery by providing key functional data in relevant primary human cells.
Cellectricon AB, a Swedish biotech company, successfully provides
groundbreaking products to the pharmaceutical and biotechnology market. The
company utilizes state-of-the-art interfaces to biological systems by
employing novel microfluidic technologies. Cellectricon's products address
critical bottlenecks in the drug discovery process and have been adopted by
top-reference customers, including nine of the top ten pharmaceutical
companies. In 2007 the company increased its annual revenue by almost 50%.
In 2008-2009 the company is launching two pioneering large-scale screening
platforms developed in close collaboration with leaders in the
pharmaceutical industry. Used in pre-clinical pharmaceutical development,
the Cellaxess(R)HT System enables high throughput RNAi screening and the
Dynaflow(R)HT System greatly advances ion channel drug discovery.
Jonas Ohlsson, CEO
VP Marketing & Communications
|SOURCE Cellectricon AB|
Copyright©2008 PR Newswire.
All rights reserved